Clinical Trials
67 trialseVOLVE-02
AstraZeneca
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
N01-A-PICIT-GT
Peking University People's Hospital
Reiki-Brachy
University of Utah
panSOHO
Bayer
DOVE
Yonsei University
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen, Inc
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Shanghai Henlius Biotech
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
PSI-Immune
University of Pittsburgh
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
Fujian Cancer Hospital
HypoRTCx-UG
Uganda Cancer Institute
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Memorial Sloan Kettering Cancer Center
PROPS GYN
Abramson Cancer Center at Penn Medicine
A Study of YL202 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
INTLECTUAL
Seoul National University Bundang Hospital
DEHIM_CCRT
Samsung Medical Center
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Yale University
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Chang Gung Memorial Hospital
Serplulimab for Locally Advanced Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Online Adaptive Radiotherapy for Cervical Cancer
Peking Union Medical College Hospital
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Tianjin Medical University Cancer Institute and Hospital
Hypofractionated Radiochemotherapy
University of Kentucky
ANA
Instituto do Cancer do Estado de São Paulo
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Women's Hospital School Of Medicine Zhejiang University
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
DURAFAK
University of Oklahoma
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Georgetown University
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
NICE-CC
Fujian Cancer Hospital
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer
Obstetrics & Gynecology Hospital of Fudan University
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).
Stanford University
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
The First Affiliated Hospital of Zhengzhou University
Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease
National Institute of CancerologÃa
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Shandong Cancer Hospital and Institute
Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
Obstetrics & Gynecology Hospital of Fudan University
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Tongji Hospital
CATPCC-01
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
PragmaTIL
Vall d'Hebron Institute of Oncology
HPV-VIM
Baylor College of Medicine